Regorafenib (REGO) +/- PD-1 inhibitor in second-line setting for unresectable hepatocellular carcinoma (uHCC) in real-world practice.
JOURNAL OF CLINICAL ONCOLOGY（2022）
关键词
hepatocellular carcinoma,unresectable hepatocellular carcinoma,inhibitor,regorafenib,second-line,real-world
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要